《藍籌業績》石藥集團(01093.HK)全年純利37.1億元人民幣升20.6% 派末期息20港仙
石藥集團(01093.HK)公布截至去年12月底止全年業績,營業額221.03億元人民幣(下同),按年升24.8%。純利37.14億元,按年升20.6%;每股盈利59.65分。派末期息20港仙,上年同期派18港仙。公司亦建議每5股發行1股紅股,惟須待股東大會批准作實。
期內,毛利為159.1億元,按年上升35.6%;經營溢利為46億元,按年上升20.3%。
於去年,按業務劃分,成藥業務收入為179.4億元,按年升32.8%;維生素C收入為19.2億元,增7.7%;抗生素收入下跌19.1%至8.79億元;其它則增長1.7%至13.7億元。
集團研發費用由13.4億元增至去年的20億元。
集團指,新上市產品則會成為新的增長動力,達新寧、舒安靈、美洛林、固邦佳等大部分均為國內獨家或首家上市的產品,且臨床需求強大,預期單一產品的市場空間能達10億至30億元。集團亦會積極參與全國藥品集中採購,借政策提供的機遇,促進普藥產品快速佔領醫院市場。
未來三年,集團預計將上市新產品50餘個,其中預計市場空間超過人民幣10億元的重磅品種將不少於15個,可強力支撐集團未來的高質量增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.